NRXP - NASDAQ
NRx Pharmaceuticals, Inc.
$4.05
-12%NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
At a Glance
Live SnapshotNRx Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
NRx Pharmaceuticals, Inc. Balance Sheet
NRXP • NASDAQ
| NRx Pharmaceuticals, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
7.8M | 1.4M | 4.6M | 20.1M | 27.6M | 1.9M | 6.0 | 11.1K | 449.4K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32M | 70.8M | 69M | |
7.8M | 1.4M | 4.6M | 20.1M | 27.6M | 1.9M | 6.0 | 11.1K | 449.4K | |
161K | 0.0 | 6K | 7K | 0.0 | 831K | 0.0 | 0.0 | 0.0 | |
161K | 0.0 | 0.0 | 0.0 | 0.0 | 831K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 6K | 7K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 214K | 0.0 | 0.0 | 0.0 | |
934K | 1.9M | 2.3M | 5.7M | 5.1M | 0.0 | 69.5K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 26K | 0.0 | 19.1K | 87K | |
8.9M | 3.3M | 6.9M | 25.8M | 32.7M | 2.9M | 69.5K | 30.2K | 536.4K | |
NON-CURRENT ASSETS | |||||||||
633K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
925K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
397K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32M | 70.8M | 69M | |
316K | 349K | 431K | 21K | 15K | 11K | 0.0 | 0.0 | 0.0 | |
4.1M | 349K | 431K | 21K | 15K | 11K | 32M | 70.8M | 69M | |
13M | 3.7M | 7.3M | 25.8M | 32.7M | 2.9M | 32.1M | 70.8M | 69.6M | |
LIABILITIES | |||||||||
CURRENT LIABILITIES | |||||||||
4.3M | 4.1M | 4.6M | 2.1M | 3.7M | 3.2M | 622.4K | 567.4K | 85.7K | |
4.3M | 4.1M | 4.6M | 2.1M | 3.7M | 3.2M | 622.4K | 551.1K | 85.7K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.3K | 0.0 | |
0.0 | 5.2M | 835K | 5.8M | 2.8M | 42.8M | 0.0 | 0.0 | 0.0 | |
316K | 1.6M | 9.2M | 7.7M | 518K | 249K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 51.6K | 69.5K | 16.3K | 0.0 | |
24M | 10.9M | 4.4M | 37K | 4.9M | 0.0 | 0.0 | 0.0 | 7.5K | |
28.6M | 21.9M | 19M | 15.6M | 11.9M | 46.2M | 622.4K | 567.4K | 93.2K | |
NON-CURRENT LIABILITIES | |||||||||
315K | 5M | 0.0 | 2.8M | 0.0 | 548K | 2M | 690K | 0.0 | |
315K | 5M | 0.0 | 2.8M | 0.0 | 548K | 2M | 690K | 0.0 | |
28.9M | 26.9M | 19M | 18.4M | 11.9M | 46.7M | 2.6M | 1.3M | 93.2K | |
SHAREHOLDERS' EQUITY | |||||||||
0.0 | 0.0 | 3K | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 | 0.0 | |
32K | 15K | 84K | 67K | 59K | 43K | 24.5M | 64.5M | 64.5M | |
290.9M | 255M | 241.3M | 230.3M | 204M | 46.4M | 4.6M | 0.0 | 5.1M | |
-306.9M | -278.3M | -253.1M | -223M | -183.2M | -90.2M | 369.5K | -38.9K | -105K | |
0.0 | 0.0 | -3K | 0.0 | 0.0 | 0.0 | -24.5M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5M | 0.0 | |
-15.9M | -23.2M | -11.7M | 7.4M | 20.8M | -43.8M | 29.5M | 69.5M | 69.5M | |
-15.9M | -23.2M | -11.7M | 7.4M | 20.8M | -43.8M | 29.5M | 69.5M | 69.5M | |
SUMMARY | |||||||||
13M | 3.7M | 7.3M | 25.8M | 32.7M | 2.9M | 32.1M | 70.8M | 69.6M | |
397K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32M | 70.8M | 69M | |
631K | 6.6M | 9.2M | 10.5M | 518K | 797K | 2M | 690K | 0.0 | |
-7.2M | 5.1M | 4.6M | -9.5M | -27.1M | -1.1M | 2M | 678.9K | -449.4K | |
19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 | 19,662,162 |
SEC Filings
NRXP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | February 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 02, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 29, 2025 | December 18, 2025 | 2025 |
Related Guides
Continue your NRXP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.